OXYSTEROLS AND METHODS OF USE THEREOF

1 . A compound of Formula (I):

or a pharmaceutically acceptable salt thereof,

wherein:

R 1 is hydrogen, C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, carbocyclyl, or heterocyclyl;

each of R 2 and R 2b is independently hydrogen, C 1 -C 6 alkyl, halo, cyano, —OR A , or —NR B R C , or

R 2a and R 2b together with the carbon atom to which they are attached form a ring (e.g., a 3-7-membered ring, e.g., a 5-7-membered ring; a ring containing at least one heteroatom, e.g., a nitrogen, oxygen, or sulfur atom);

each of R 4a and R 4b is independently absent, hydrogen, C 1 -C 6 alkyl, or halo;

X is —C(R X ) 2 — or —O—, wherein R X is independently hydrogen, halo, or one R X group and R 5b are joined to form a double bond;

Y is —OR Y , wherein R is hydrogen, C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, carbocyclyl, heterocyclyl, aryl, heteroaryl, —C(O)R A , —C(O)OR A , —C(O)NR B R C , or —S(O) 2 R D ;

each instance of R 5a and R 5b is independently hydrogen, halo, or C 1 -C 6 alkyl;

each of R 6a and R 6b is independently hydrogen, C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, carbocyclyl, heterocyclyl, aryl, or heteroaryl, or

R 6a and R 6b , taken together with the carbon atom to which they are attached, form a ring (e.g., a 3-6-membered ring, e.g. a 4-6-membered ring containing one heteroatom); or

R 5a and R 6a , together with the carbon atoms to which they are attached, form a ring (e.g., a 3-6-membered ring, e.g. a 4-6-membered ring containing one heteroatom); and

R 7 is absent or hydrogen in the alpha configuration;

R 8 is hydrogen, halo, C 1-6 alkyl, carbocyclyl, or —OR A ;

represents a single or double bond, wherein when one is a double bond, the other is a single bond;

wherein when the between —CR 7 and —CR 4a R 4b is a double bond, then one of R 4a or R 4b is absent; and

when one of the is a double bond, R 7 is absent;

R A is hydrogen, C 1 -C 6 alkyl, carbocyclyl, heterocyclyl, aryl, or heteroaryl;

each of R B and R C is independently hydrogen, C 1 -C 6 alkyl, carbocyclyl, heterocyclyl, aryl, heteroaryl, or taken together with the atom to which they are attached form a ring (e.g., a 3-7-membered ring, e.g., a 5-7-membered ring; a ring containing at least one heteroatom, e.g., a nitrogen, oxygen, or sulfur atom); and

R D is hydrogen, C 1 -C 6 alkyl, carbocyclyl, heterocyclyl, aryl, or heteroaryl.

2 . The compound of claim 1 , or the pharmaceutically

acceptable salt thereof, wherein:

a. R 1 is unsubstituted C 1-3 alkyl;

b. R 1 is —CH 3 , —CH 2 CH 3 , or —CH 2 CH 2 CH 3 ;

c. R 1 is substituted C 1-3 alkyl; or

d. R 1 is haloalkyl (e.g., —CF 3 ) or —CH 2 OCH 3 .

3 - 5 . (canceled)

6 . The compound of claim 1 , or the pharmaceutically acceptable salt thereof, wherein:

a. R 2a or R 2b is hydrogen; or

b. R 2a and R 2b are both hydrogen.

7 . (canceled)

8 . The compound of claim 1 , or the pharmaceutically acceptable salt thereof, wherein R 4a is hydrogen.

9 . The compound of claim 1 , or the pharmaceutically acceptable salt thereof, wherein X is —CH 2 —.

10 . The compound of claim 1 , or the pharmaceutically acceptable salt thereof, wherein:

a. R is substituted or unsubstituted C 1-3 alkyl; or

b. R 8 is —CH 3 .

11 . (canceled)

12 . The compound of claim 1 , or the pharmaceutically acceptable salt thereof, wherein the compound of Formula (I) is a compound of Formula (II):

13 . The compound of claim 12 , or the pharmaceutically acceptable salt thereof, wherein the compound of Formula (II) is a compound of Formula (II-A):

14 . The compound of claim 12 , or the pharmaceutically acceptable salt thereof, wherein the compound of Formula (II) is a compound of Formula (II-B):

15 . The compound of claim 1 , or the pharmaceutically acceptable salt thereof, wherein:

a R 5a or R 5b is hydrogen; or

b. R 5a and R 5b are both hydrogen.

16 . (canceled)

17 . The compound of claim 1 , or the pharmaceutically acceptable salt thereof, wherein:

a. R 6a is a substituted or unsubstituted C 1-3 alkyl;

b. R 6a is —CH 3 or —CH 2 CH 3 ; or

c. R 6a is a substituted or unsubstituted C 2-4 alkyl, substituted or unsubstituted C 2-3 alkenyl, substituted or unsubstituted C 2-3 alkynyl, or substituted or unsubstituted carbocyclyl.

18 .- 19 . (canceled)

20 . The compound of claim 1 , or the pharmaceutically acceptable salt thereof, wherein:

a. R 6b is substituted or unsubstituted C 1-3 alkyl;

b. R 6b is —CH 3 or —CH 2 CH 3 ;

c. R 6b is hydrogen; or

d. R 6b is —CH 3 or —CF 3 .

21 .- 23 . (canceled)

24 . The compound of claim 1 , or the pharmaceutically acceptable salt thereof, wherein:

a. R 6a and R 6b are both —CH 3 ;

b. R 6a and R 6b , taken together with the atom to which they are attached, form a ring; or

c. R 6a and R 6b , taken together with the atom to which they are attached, form a 3-membered ring.

25 .- 26 . (canceled)

27 . The compound of claim 1 , or the pharmaceutically acceptable salt thereof, wherein R 1 is hydrogen or C 1-3 alkyl, R 6a is substituted or unsubstituted C 1-3 alkyl, substituted or unsubstituted C 2-3 alkenyl, substituted or unsubstituted C 2-3 alkynyl, or substituted or unsubstituted carbocyclyl, and R 6b is —CH 3 .

28 . The compound of claim 27 , or the pharmaceutically acceptable salt thereof, wherein:

a. R 6a is selected from the group consisting of substituted or unsubstituted C 1-3 alkyl, unsubstituted C 2-3 alkenyl, unsubstituted C 2-3 alkynyl, or unsubstituted carbocyclyl; or

b. R 6a is selected from a substituted or unsubstituted C 1-3 alkyl.

29 . (canceled)

30 . The compound of claim 1 , or the pharmaceutically acceptable salt thereof, wherein R 1 is —CH 3 or —CH 2 CH 3 and R 6b is —CH 3 or —CF 3 .

31 . The compound of claim 1 , or the pharmaceutically acceptable salt thereof, wherein:

a. R Y is substituted or unsubstituted C 1-3 alkyl;

b. R Y is substituted or unsubstituted heterocyclyl;

c. R is —CH 3 ; or

d. R Y is —CF 3 .

32 .- 34 . (canceled)

35 . The compound of claim 1 , or the pharmaceutically acceptable salt thereof, wherein the compound is:

36 . A pharmaceutical composition comprising a compound or pharmaceutically acceptable salt thereof according to claim 1 , and a pharmaceutically acceptable carrier.

37 . A method of inducing sedation or anesthesia comprising administering to a subject an effective amount of a compound or pharmaceutically acceptable salt thereof according to claim 1 , or pharmaceutical composition thereof.

38 . A method for treating or preventing a disorder, comprising administering to a subject in need thereof an effective amount of a compound of or pharmaceutically acceptable salt thereof according to claim 1 , or pharmaceutical composition thereof;

wherein the disorder is selected from the group consisting of a gastrointestinal (GI) disorder, inflammatory bowel disease (IBD), a structural disorder affecting the GI, an anal disorder, a colon polyp, cancer, diabetes, a sterol synthesis disorder, and colitis.

39 .- 41 . (canceled)

42 . A method for treating or preventing a CNS-related condition comprising administering to a subject in need thereof an effective amount of a compound or pharmaceutically acceptable salt thereof according to claim 1 , or pharmaceutical composition thereof.

43 . The method according to claim 42 , wherein the CNS-related condition is an adjustment disorder, anxiety disorder, cognitive disorder, dissociative disorder, eating disorder, mood disorder, schizophrenia or other psychotic disorder, disorder, substance-related disorder, personality disorder, autism spectrum disorders, neurodevelopmental disorder, multiple sclerosis, sterol synthesis disorders, pain, encephalopathy secondary to a medical condition, seizure disorder, stroke, traumatic brain injury, movement disorder, vision impairment, hearing loss, and tinnitus.

44 . (canceled)